Rocket Pharmaceuticals, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $47.6 million, a decrease from the $61.3 million loss recorded in the same period of 2025. The company did not generate any revenue during this quarter, consistent with its previous performance. Operating expenses totaled $48.5 million, down from $64.4 million year-over-year, primarily due to reduced research and development (R&D) and general administrative costs. R&D expenses decreased to $31.5 million from $35.9 million, while general and administrative expenses fell to $17.1 million from $28.4 million.
The company’s cash and cash equivalents stood at $49.6 million as of March 31, 2026, a decline from $77.6 million at the end of 2025. Total assets decreased to $285.4 million from $330.4 million, while total liabilities also decreased to $47.4 million from $53.2 million. The accumulated deficit increased to $1.49 billion, reflecting ongoing operational losses. Rocket's financial position is bolstered by an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $180 million, which is expected to provide non-dilutive capital to support its cardiovascular gene therapy pipeline.
Strategically, Rocket Pharmaceuticals has focused on its AAV-based gene therapy platform, particularly for cardiovascular diseases. The company received FDA accelerated approval for its gene therapy KRESLADI™ in March 2026, aimed at treating severe Leukocyte Adhesion Deficiency-I (LAD-I). This approval is a significant milestone, although the company does not anticipate generating material revenue from KRESLADI™ in the near term due to the ultra-rare patient population. The company is also advancing its clinical programs for Danon disease and Plakophilin-2 Arrhythmogenic Cardiomyopathy, with ongoing trials and regulatory submissions.
Operationally, Rocket has undergone a restructuring initiative, which included a workforce reduction of approximately 30% to align resources with its highest-priority programs. The company is also enhancing its in-house manufacturing capabilities to support its gene therapy products. As of March 31, 2026, Rocket had approximately 109 million shares outstanding, reflecting a slight increase from the previous quarter. The company continues to evaluate potential strategic partnerships to further its development efforts and is focused on maintaining its operational runway through careful capital management. Looking ahead, Rocket expects to continue incurring losses as it invests in R&D and prepares for the commercialization of its therapies.
About ROCKET PHARMACEUTICALS, INC.
Rocket Pharmaceuticals is a biotech company specializing in developing gene therapies for rare, devastating diseases. Its focus includes in vivo AAV-based treatments for conditions like Danon disease and cardiomyopathies, as well as ex vivo lentiviral programs for hematologic disorders such as Fanconi anemia and LAD-I. The company aims to deliver potentially curative, first-in-class therapies targeting unmet medical needs in pediatric and adult patients worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.